Stock Comparison
REGN vs URGN
Regeneron Pharmaceuticals Inc and UroGen Pharma Ltd side by side — valuation, profitability, growth and risk.
Valuation
Market Cap
$80.55B
$2.38B
P/E (TTM)
19.4
—
Forward P/E
17.1
—
Price/Sales
5.2
12.6
Price/Book
2.5
16.9
EV/EBITDA
13.1
-2.7
Dividend Yield
0.45%
—
Profitability
Net Margin
29.65%
-94.83%
Operating Margin
24.32%
-77.02%
Return on Equity
14.00%
-1481.00%
Return on Assets
6.53%
-18.10%
Growth (YoY)
Revenue Growth
16.70%
199.20%
Earnings Growth
-4.50%
0.00%
Price & Risk
Beta
0.2
1.6
52-Week High
$810.12
$49.00
52-Week Low
$553.38
$16.42
Analyst Target
$833.54
$58.25
Compare REGN and URGN your own way
Try mrmarket.ai freeFigures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.